TDTaranika Sarkar Das

Taranika Sarkar Das

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taranika Sarkar Das has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Surgical Hemorrhoidectomy Unexpectedly Resulting in Diagnosis of Mucosal Melanoma

    by Zohyra E. Zabala, Taranika Sarkar Das, Wendy Garzon, Ali Wakil, Chanakya Nayudu, Ivette Vigoda, Sushma Venugopal

    An abstract is unavailable. This article is available as a PDF only.

  • Open Access

    Saline-tunneling endoscopic submucosal dissection for residual rectal lesion at anastomotic staple line

    by Taranika Sarkar Das, Prabhleen Chahal, Matheus Franco

  • Open Access

    An Assessment of the Feasibility, Patient Acceptance, and Performance of Point-of-Care Transient Elastography for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis

    by Taranika Sarkar Das, Xucong Meng, Mohamed Abdallah, Mohammad Bilal, Raiya Sarwar, Aasma Shaukat

    Background: Vibration-Controlled Transient Elastography (VCTE) with FibroScan is a non-invasive, reliable diagnostic tool for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD), enabling early detection and management to prevent severe liver diseases. VCTE’s ease and portability suit primary care, streamlining referrals, promoting lifestyle changes, reducing costs, and benefiting underserved communities. Methods: Studies on point-of-care VCTE were systematically reviewed, followed by meta-analysis using a random-effects model. Pooled proportions with 95% confidence intervals were reported, and heterogeneity was assessed using I2%. Results: A total of twenty studies from 14 countries, including 6159 patients, were analyzed, with three studies from France, two from the U.S., and four from China. The population had a slight male preponderance, with a mean age range of 35–73 years and a BMI range of 24.4–41.1%. The diagnostic accuracy for detecting any fibrosis (≥F1) was reported in four studies (n = 210) with an AUC of 0.74, sensitivity of 69.5%, and specificity of 70.6%. For significant fibrosis (≥F2), eight studies (n = 650) reported an AUC of 0.69, sensitivity of 81.7%, and specificity of 64.6%. Advanced fibrosis (≥F3) was evaluated in 10 studies (n = 619), with an AUC of 0.84, sensitivity of 88.1%, and specificity of 63.8%. Cirrhosis (F4) was assessed in nine studies (n = 533), with an AUC of 0.65, sensitivity of 87.5%, and specificity of 62.6%. Steatosis diagnoses across stages S1 to S3 showed increasing diagnostic accuracies, with AUCs of 0.85, 0.76, and 0.80, respectively. Probe type and BMI were significant covariates influencing diagnostic performance for both fibrosis and steatosis, while the percentage of male participants also showed significant associations. Conclusions: VCTE shows high diagnostic accuracy for fibrosis and steatosis in MASLD patients at the point of care. Future research should assess its implementation in fibroscan settings.


  • Risk of colorectal cancer in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease compared with primary sclerosing cholangitis only

    by Taranika Sarkar Das, Kimberly Ho, Jahnavi Udaikumar, Bryan Chen, Olivia Delau, Aasma Shaukat, Ira Jacobson, Raiya Sarwar

    Aim: Primary sclerosing cholangitis (PSC) increases the risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients; however, there is a paucity of literature to suggest PSC alone as an independent risk factor for CRC. We aimed to determine if PSC is an independent risk factor for CRC in a large tertiary care medical center. Optimizing screening intervals is of great importance, given the burden and risks associated with a lifetime of colonoscopy screening.Methods: This retrospective cohort study consists of patients diagnosed with PSC preceding IBD (PSC–IBD) and PSC‐only before January 6, 2023 from a large, tertiary, academic medical center. Patients diagnosed with IBD concurrently or before PSC were excluded to reduce IBD's impact on CRC risk. Demographic data and colonoscopy findings were collected and assessed.Results: Overall, 140 patients from all NYU Langone Health clinical settings were included. Patients with PSC–IBD were more likely to be diagnosed with CRC (23.3% vs. 1.8%, p < 0.01) and either low‐grade or uncharacterized dysplasia (16.7% vs. 0.0%, p < 0.01) compared with those with PSC‐only. Among PSC‐only patients, the estimated CRC risk was significantly elevated compared with that expected of the standard NYU Langone population (SIR 9.2, 95% CI 1.1, 33.2).Conclusions: Our study revealed a significantly heightened CRC risk in PSC–IBD patients compared with those with PSC‐only. Importantly, individuals with PSC‐only also face a greater CRC risk compared with the general population. Individuals with PSC‐alone may require extended screening and surveillance colonoscopy intervals compared with those with PSC–IBD, yet still require more frequent monitoring than screening guidelines recommend for the general population.


  • Open Access

    A case of Methicillin-sensitive Staphylococcus aureus infective endocarditis that rapidly changed prognosis in a patient with cirrhosis: An atypical case with literature review

    by Taranika Sarkar, Kaushik Doshi, Avani Patel, Babu P Mohan

    Bacterial infections represent a major cause of mortality and morbidity in patients with cirrhosis that can alter the clinical course of compensated cirrhosis. The most common infections are spontaneous bacterial peritonitis by gram-negative organisms, urinary-tract infection, and pneumonia. In this case report, we raise the question of considering infections in the prognosis scoring in this patient group.


  • Open Access

    A Case of Late Presentation of Pancreatic Divisum in a Patient with Recurrent Pancreatitis

    by Taranika Sarkar, Sophia Jagroop

    Pancreatic Divisum (PD) is the most common congenital variation of pancreatic duct anatomy, arising when embryological ventral and dorsal endodermal buds fail to fuse ("classic" PD) or only fuse partially ("incomplete" PD). Most patients with PD are asymptomatic, but a subgroup of patients can present with recurrent bouts of pancreatitis. While alcohol and gallstones are the common causes of acquired pancreatitis, PD is a congenital cause of pancreatitis. It is usually suspected in younger individuals with recurrent pancreatitis who also have a family history. Here, we present a rare case of PD in an older individual who presented with recurrent pancreatitis. He underwent cholecystectomy for suspected gallstone pancreatitis but continued to have episodes of pancreatitis. He had a history of alcohol abuse but denied use in the last one year. PD was detected later as the cause. Recurrent pancreatitis led to the development of a pseudocyst and pancreaticopleural fistula (PPF). Medical management improved the pseudocyst and PPF.


  • Open Access

    Emergence of Azole Resistant Candida Glabrata as an Important Cause of Hospital Acquired Infection: Its Risk Factors and Impact

    by Sarkar T

    Candida spp. colonizes the human host and coexists with members of the human microbiome. Candida glabrata are aggressive pathogens, have many virulence factors that lead to serious recurrent candidiasis. Their ability to form a complex biofilm, inability to form hyphae, and inability to secrete hydrolase lead to antifungal resistance. Candidemia is the fourth most common bloodstream infection [1]. Candidemia remains a major source of mortality and morbidity. Mortality among patients with invasive candidiasis is as high as 40%, even when patients receive antifungal therapy [2]. More than 90% of invasive diseases are caused by the 5 most common Candida spp. C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei [3]. The distribution of Candida species has been changing over the last decade, with a decrease in the proportion of C. albicans and an increase in C. glabrata and C. parapsilosis. More than 50% of bloodstream infections are caused by non-albicans Candida [2,4]. The largest proportional increase in the USA is in C. glabrata, which accounts for one third or more of all candidemia isolates [5-7]. C.glabrata are associated with high mortality. Candida glabrata develop acquired resistance following exposure to antifungal agents [8]. 50% of C. glabrata are resistant to fluconazole [9,10]. Furthermore, 9% of C. glabrata that are resistant to fluconazole are also resistant to the echinocandins [8,11].